JP6559228B2 - 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 - Google Patents
肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 Download PDFInfo
- Publication number
- JP6559228B2 JP6559228B2 JP2017514665A JP2017514665A JP6559228B2 JP 6559228 B2 JP6559228 B2 JP 6559228B2 JP 2017514665 A JP2017514665 A JP 2017514665A JP 2017514665 A JP2017514665 A JP 2017514665A JP 6559228 B2 JP6559228 B2 JP 6559228B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- mmol
- cycloalkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*1C=C(C(*)CN(Cc2ccc(C(*)(*)N*)cc2)C2*)C2=CC=C1 Chemical compound C*1C=C(C(*)CN(Cc2ccc(C(*)(*)N*)cc2)C2*)C2=CC=C1 0.000 description 6
- YRJRLQQYYUMFSI-UHFFFAOYSA-N CC(C)(C)OC(N(CCc1c2OC)Cc1ccc2OCc1ccccc1)=O Chemical compound CC(C)(C)OC(N(CCc1c2OC)Cc1ccc2OCc1ccccc1)=O YRJRLQQYYUMFSI-UHFFFAOYSA-N 0.000 description 1
- GFTZWHWPCWTGSJ-ZHACJKMWSA-N COc1c(/C=C/[NH+]([O-])[O-])cccc1OCc1ccccc1 Chemical compound COc1c(/C=C/[NH+]([O-])[O-])cccc1OCc1ccccc1 GFTZWHWPCWTGSJ-ZHACJKMWSA-N 0.000 description 1
- DDLPRAKDATZHQQ-UHFFFAOYSA-N COc1c(CCN)cccc1OCc1ccccc1 Chemical compound COc1c(CCN)cccc1OCc1ccccc1 DDLPRAKDATZHQQ-UHFFFAOYSA-N 0.000 description 1
- VOPRWDOBVZGFRH-UHFFFAOYSA-N OC(C1)c2cc(O)ccc2CN1C(OC(CI)(CI)CI)=O Chemical compound OC(C1)c2cc(O)ccc2CN1C(OC(CI)(CI)CI)=O VOPRWDOBVZGFRH-UHFFFAOYSA-N 0.000 description 1
- AONJPTOQPBDGOS-UHFFFAOYSA-N OC(C1)c2cc(OCC3CC3)ccc2CN1C(OC(CI)(CI)CI)=O Chemical compound OC(C1)c2cc(OCC3CC3)ccc2CN1C(OC(CI)(CI)CI)=O AONJPTOQPBDGOS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185224.4 | 2014-09-17 | ||
| EP14185224 | 2014-09-17 | ||
| PCT/EP2015/070741 WO2016041845A1 (en) | 2014-09-17 | 2015-09-10 | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528485A JP2017528485A (ja) | 2017-09-28 |
| JP2017528485A5 JP2017528485A5 (enExample) | 2018-10-18 |
| JP6559228B2 true JP6559228B2 (ja) | 2019-08-14 |
Family
ID=51564524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514665A Expired - Fee Related JP6559228B2 (ja) | 2014-09-17 | 2015-09-10 | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9340510B2 (enExample) |
| EP (1) | EP3194367B1 (enExample) |
| JP (1) | JP6559228B2 (enExample) |
| WO (1) | WO2016041845A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7114702B2 (ja) | 2017-07-11 | 2022-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換キサンチン誘導体 |
| US11459324B2 (en) * | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| AR122756A1 (es) * | 2020-07-02 | 2022-10-05 | Pfizer | Preparación de un derivado de pirimidinil-3,8-diazabiciclo[3.2.1]octanilmetanona y sal de este |
| JPWO2023090411A1 (enExample) | 2021-11-19 | 2023-05-25 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69829875T2 (de) | 1997-10-14 | 2006-03-09 | Mitsubishi Pharma Corp. | Piperazin-verbindungen und ihre medizinische verwendung |
| MXPA01011173A (es) * | 1999-05-06 | 2002-04-24 | Neurogen Corp | 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba. |
| JP2004143134A (ja) * | 2002-02-13 | 2004-05-20 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| CN101107247B (zh) * | 2004-11-30 | 2011-10-19 | 霍夫曼-拉罗奇有限公司 | 作为用于治疗糖尿病的dpp-iv抑制剂的取代的苯并喹嗪衍生物 |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| EP2297164A1 (en) * | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| US20100280067A1 (en) * | 2009-04-30 | 2010-11-04 | Pakala Kumara Savithru Sarma | Inhibitors of acetyl-coa carboxylase |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| CN102451178A (zh) | 2010-10-29 | 2012-05-16 | 中国科学院上海药物研究所 | 二氢呋喃-2-酮类化合物在制备抗糖尿病及糖脂代谢药物中的用途 |
-
2015
- 2015-09-10 EP EP15760470.3A patent/EP3194367B1/en active Active
- 2015-09-10 JP JP2017514665A patent/JP6559228B2/ja not_active Expired - Fee Related
- 2015-09-10 WO PCT/EP2015/070741 patent/WO2016041845A1/en not_active Ceased
- 2015-09-16 US US14/855,668 patent/US9340510B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160075657A1 (en) | 2016-03-17 |
| US9340510B2 (en) | 2016-05-17 |
| EP3194367B1 (en) | 2021-08-18 |
| WO2016041845A1 (en) | 2016-03-24 |
| EP3194367A1 (en) | 2017-07-26 |
| JP2017528485A (ja) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6130398B2 (ja) | 新規アゼチジン誘導体、その医薬組成物及び使用 | |
| JP6130399B2 (ja) | 新規アゼチジン誘導体、医薬組成物およびそれらの使用 | |
| JP5654675B2 (ja) | ピペリジン誘導体及び代謝障害の治療のためのそれらの使用 | |
| JP6048406B2 (ja) | 新規化合物、医薬組成物及びこれらの使用 | |
| JP6047825B2 (ja) | ピロリジン誘導体、その医薬組成物及び使用 | |
| JP6244591B2 (ja) | 新規ピロリジン誘導体及びそれらのアセチルｃｏａカルボキシラーゼ阻害薬としての使用 | |
| JP5928737B2 (ja) | エチン誘導体、医薬組成物及びその使用 | |
| JP6446433B2 (ja) | ピリミジン置換ピロリジン誘導体、医薬組成物及びこれらの使用 | |
| TW201002696A (en) | Novel compounds 409 | |
| JP6378752B2 (ja) | ピロリジン誘導体、その医薬組成物及び使用 | |
| JP2017528485A (ja) | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 | |
| JP6098001B2 (ja) | 新規ピペリジン誘導体、その医薬組成物及び使用 | |
| JP6129199B2 (ja) | ピペリジン誘導体、その医薬組成物及び使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180907 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190415 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190614 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190708 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190716 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6559228 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |